These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30376324)

  • 21. Predicting toxicities of reactive metabolite-positive drug candidates.
    Kalgutkar AS; Dalvie D
    Annu Rev Pharmacol Toxicol; 2015; 55():35-54. PubMed ID: 25292426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Topological structural alerts modulations of mammalian cell mutagenicity for halogenated derivatives.
    Pérez-Garrido A; Girón-Rodríguez F; Morales Helguera A; Borges F; Combes RD
    SAR QSAR Environ Res; 2014; 25(1):17-33. PubMed ID: 24283490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrated decision support for assessing chemical liabilities.
    Spjuth O; Eklund M; Ahlberg Helgee E; Boyer S; Carlsson L
    J Chem Inf Model; 2011 Aug; 51(8):1840-7. PubMed ID: 21774475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of the structural requirements for mutagencitiy, by incorporating molecular flexibility and metabolic activation of chemicals. II. General Ames mutagenicity model.
    Serafimova R; Todorov M; Pavlov T; Kotov S; Jacob E; Aptula A; Mekenyan O
    Chem Res Toxicol; 2007 Apr; 20(4):662-76. PubMed ID: 17381132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Different Methods for Identification of Structural Alerts Using Chemical Ames Mutagenicity Data Set as a Benchmark.
    Yang H; Li J; Wu Z; Li W; Liu G; Tang Y
    Chem Res Toxicol; 2017 Jun; 30(6):1355-1364. PubMed ID: 28485959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A practice of expert review by read-across using QSAR Toolbox.
    Fukuchi J; Kitazawa A; Hirabayashi K; Honma M
    Mutagenesis; 2019 Mar; 34(1):49-54. PubMed ID: 30690463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Silico Prediction of Chemically Induced Mutagenicity: How to Use QSAR Models and Interpret Their Results.
    Mombelli E; Raitano G; Benfenati E
    Methods Mol Biol; 2016; 1425():87-105. PubMed ID: 27311463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Deep Learning-Based Chemical System for QSAR Prediction.
    Hu S; Chen P; Gu P; Wang B
    IEEE J Biomed Health Inform; 2020 Oct; 24(10):3020-3028. PubMed ID: 32142459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Ursem CJ; Kruhlak NL; Benz RD; Sabaté DA; Yang C; Klopman G; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):23-42. PubMed ID: 19422098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A topological substructural molecular design approach for predicting mutagenesis end-points of alpha, beta-unsaturated carbonyl compounds.
    Pérez-Garrido A; Helguera AM; López GC; Cordeiro MN; Escudero AG
    Toxicology; 2010 Jan; 268(1-2):64-77. PubMed ID: 20004227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flexible use of QSAR models in predictive toxicology: a case study on aromatic amines.
    Benigni R; Bossa C
    Environ Mol Mutagen; 2012 Jan; 53(1):62-9. PubMed ID: 22329023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data.
    Matthews EJ; Kruhlak NL; Benz RD; Contrera JF
    Curr Drug Discov Technol; 2004 Jan; 1(1):61-76. PubMed ID: 16472220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities.
    Matthews EJ; Kruhlak NL; Benz RD; Aragonés Sabaté D; Marchant CA; Contrera JF
    Regul Toxicol Pharmacol; 2009 Jun; 54(1):43-65. PubMed ID: 19422100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In Silico Prediction of Chemical Toxicity Profile Using Local Lazy Learning.
    Lu J; Zhang P; Zou XW; Zhao XQ; Cheng KG; Zhao YL; Bi Y; Zheng MY; Luo XM
    Comb Chem High Throughput Screen; 2017; 20(4):346-353. PubMed ID: 28215144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.
    Chen M; Hong H; Fang H; Kelly R; Zhou G; Borlak J; Tong W
    Toxicol Sci; 2013 Nov; 136(1):242-9. PubMed ID: 23997115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability domains for classification problems: Benchmarking of distance to models for Ames mutagenicity set.
    Sushko I; Novotarskyi S; Körner R; Pandey AK; Cherkasov A; Li J; Gramatica P; Hansen K; Schroeter T; Müller KR; Xi L; Liu H; Yao X; Öberg T; Hormozdiari F; Dao P; Sahinalp C; Todeschini R; Polishchuk P; Artemenko A; Kuz'min V; Martin TM; Young DM; Fourches D; Muratov E; Tropsha A; Baskin I; Horvath D; Marcou G; Muller C; Varnek A; Prokopenko VV; Tetko IV
    J Chem Inf Model; 2010 Dec; 50(12):2094-111. PubMed ID: 21033656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. QSAR without borders.
    Muratov EN; Bajorath J; Sheridan RP; Tetko IV; Filimonov D; Poroikov V; Oprea TI; Baskin II; Varnek A; Roitberg A; Isayev O; Curtarolo S; Fourches D; Cohen Y; Aspuru-Guzik A; Winkler DA; Agrafiotis D; Cherkasov A; Tropsha A
    Chem Soc Rev; 2020 Jun; 49(11):3525-3564. PubMed ID: 32356548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive QSAR modeling workflow, model applicability domains, and virtual screening.
    Tropsha A; Golbraikh A
    Curr Pharm Des; 2007; 13(34):3494-504. PubMed ID: 18220786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing around Structural Alerts in Drug Discovery.
    Kalgutkar AS
    J Med Chem; 2020 Jun; 63(12):6276-6302. PubMed ID: 31497963
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.